ARCH Venture Partners has closed ARCH Venture Fund XII with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies.
This new fund follows the January 2021 announcement of the $1.941 Billion ARCH Venture Fund XI.
ARCH investments made from Fund XII will reflect the firm’s focus on companies formed around breakthrough technologies. This means investing in early stage biotechnology companies with potential to solve some of the biggest health challenges in areas including infectious disease, mental health, immunology, oncology, neurology, age-related diseases, manufacturing, clinical trials, genomic and biological tools, data sciences, and ways to reimagine diagnostics and therapies.
Read more: Private Equity Wire
